Benzinga · Mar 4, 2026
Vir Biotechnology CEO Marianne De Backer To Additional Role Of President, Effective Immediately
SEC.
VI
NASDAQ · VIR
Vir Biotechnology, Inc.
Healthcare · Biotechnology
$9.78
Up+$0.57 (+6.19%)
Updated Aug 22, 2026, 4:12 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 923.02M
- P/E ratio
- -1.67
- Dividend yield
- 0.00%
- 52-week range
- $4.75 – $11.66
- Volume
- 1.76M
- Avg. volume
- 1.53M
Price performance
VIR price history
1M range · 0 trading sessions · Daily adjusted prices
VIR does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest VIR news
The latest Smart Investors Daily articles mentioning VIR.
Stock researchCompany · Overview
VIR research
Overview
Company profile and research snapshot.
Company profile
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $12.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 11, 2026 | Morgan Stanley | Overweight | — |
| Jun 3, 2026 | Leerink Partners | Outperform | — |
| Mar 4, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 25, 2026 | Barclays | Overweight | — |
| Feb 24, 2026 | Evercore ISI Group | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 4, 2026
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $20
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $15 to $20.
SeekingAlpha · Mar 3, 2026
Vir Biotechnology, Inc. (VIR) Presents at 2026 ASCO Genitourinary Cancers Symposium - Slideshow
Benzinga · Feb 26, 2026
Reported Earlier, Vir Biotechnology Prices Public Offering Of 17,647,058 Common Shares At $8.50 Per Share, Raising $150M To Advance Infectious Disease And Cancer Pipeline
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
